Exscientia Holdings Limited (EXAI) News
Filter EXAI News Items
EXAI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EXAI News Highlights
- EXAI's 30 day story count now stands at 7.
- Over the past 16 days, the trend for EXAI's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- DRUG, DXCM and PRE are the most mentioned tickers in articles about EXAI.
Latest EXAI News From Around the Web
Below are the latest news stories about EXSCIENTIA PLC that investors may wish to consider to help them evaluate EXAI as an investment opportunity.
Wall Street Analysts See a 67.76% Upside in Exscientia PLC Sponsored ADR (EXAI): Can the Stock Really Move This High?The consensus price target hints at a 67.8% upside potential for Exscientia PLC Sponsored ADR (EXAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia ProgrammeOXFORD, England, December 21, 2023--Exscientia plc (Nasdaq: EXAI) today announced that Sanofi is adding a new discovery stage programme identified and initially advanced by Exscientia into the current collaboration. In this programme, Exscientia has designed a novel lead series with a potential best in class profile, with preliminary data showing good potency and selectivity towards the target and differentiated molecular properties. |
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?Here is how DexCom (DXCM) and Exscientia PLC Sponsored ADR (EXAI) have performed compared to their sector so far this year. |
Looking for the Next Big Thing? Add This AI Biotech to Your Watch List Right NowExscientia (NASDAQ: EXAI) is one such business undertaking this effort, and it's worth adding to your watch list today. Much like the other biotech businesses hoping to use AI for drug development, Exscientia believes that its AI-based platform can shorten development timelines, reduce failure rates in pre-clinical and clinical trials, and lower costs for drug makers. Exscientia's flagship program is cancer treatment candidate GTAEXS617. |
Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In NovemberThe AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions. |
We Think Exscientia (NASDAQ:EXAI) Needs To Drive Business Growth CarefullyWe can readily understand why investors are attracted to unprofitable companies. For example, although... |
Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic InfluenzaOXFORD, England, December 05, 2023--Exscientia plc (Nasdaq: EXAI) announced today that the Company received a $2.3 million grant from Open Philanthropy, a philanthropic funder with several programs in global health and wellbeing. Under this grant, Exscientia aims to harness the activation of the host interferon response as a therapeutic approach for pandemic influenza. |
Wall Street Analysts Think Exscientia PLC Sponsored ADR (EXAI) Could Surge 68.03%: Read This Before Placing a BetThe mean of analysts' price targets for Exscientia PLC Sponsored ADR (EXAI) points to a 68% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Is Dynavax Technologies (DVAX) Stock Outpacing Its Medical Peers This Year?Here is how Dynavax Technologies (DVAX) and Exscientia PLC Sponsored ADR (EXAI) have performed compared to their sector so far this year. |
Exscientia to Present at the 6th Annual Evercore ISI HealthCONx ConferenceOXFORD, England, November 21, 2023--Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 3:25 p.m. EST (8:25 p.m. GMT). |